Company: Hangzhou Diagens Biotechnology Co., Ltd.

Date of Prospectus: March 20, 2026

Hangzhou Diagens Biotechnology Co., Ltd. IPO: Deep-Dive Analysis of Offer Price, Financials, Risks, and Growth Prospects

IPO Snapshot: Offer Price, Shares, Symbol, and Timetable

Hangzhou Diagens Biotechnology Co., Ltd. launches its IPO as a pioneering biotechnology firm specializing in AI-powered medical diagnostics, targeting investors with a growth-driven story. The company seeks a listing on the Main Board of the Hong Kong Stock Exchange under Chapter 18A, with its core product, AI AutoVision®, in the registration stage and planned indication expansion in early clinical development [[10]].

• IPO Symbol: Not disclosed in the document.
• Offer Price Range: HK\$95.6 to HK\$112.5 per H Share [[27]].
• Total Offer Size: 7,999,200 H Shares in the Global Offering [[27]].
• Post-IPO Outstanding Shares: 88,879,200 Shares [[373]].
• Expected Market Capitalization: HK\$8,496.9 million to HK\$9,998.9 million [[27]].
• Application Window: March 20, 2026 (9:00 a.m.) to March 25, 2026 (12:00 noon) [[5], [296]].
• Listing Date: March 30, 2026 [[6], [33]].

Use of Proceeds: Growth-Driven Allocation and Expansion Plans

Proceeds from the IPO are earmarked for R&D, commercialization, and expansion, highlighting a growth-centric strategy. Net proceeds will be allocated as follows [[278]]:

• R&D and clinical development of AI AutoVision® and MetaSight®
• Expansion of commercial capabilities and market penetration
• General working capital and potential strategic investments

This allocation underscores the company’s focus on scaling technology-driven diagnostics and increasing market share, rather than deleveraging.

IPO Allocation: Placement Breakdown, Dividend Policy, and Subscription Metrics

The Global Offering consists of a Hong Kong Public Offering (10% of shares) and an International Offering (90%). The Hong Kong Public Offering is open to retail and institutional investors. Reallocation mechanisms allow up to 15% of shares to be shifted if oversubscription occurs [[289], [290]].

• Dividend Policy: No specific payout ratio or timetable disclosed; future dividends are subject to company performance [[43]].
• Placement Breakdown:
  • Public Offering: 799,950 H Shares
  • International Offering: 7,199,250 H Shares
• Employee/ESOP Allocation: Not specifically disclosed.
• Oversubscription Metrics: Not provided; results to be announced post-allotment [[302]].

Investor Participation and Book Quality

Institutional and professional investors are anticipated to participate heavily in the International Offering. The book-building process involves selective marketing to investors anticipated to have sizeable demand, aiming to establish a solid shareholder base [[291]].

• No anchor or cornerstone investors named.
• No pre-listing disposals by early shareholders disclosed.
• Book quality and first-day performance will be inferred from allocation results, which will be published post-offer [[302]].

Deal Parties, Underwriters, and Listing Structure

The IPO is managed by top-tier financial institutions, potentially supporting a robust listing-day performance.

• Sole Sponsor: Huatai Financial Holdings (Hong Kong) Limited [[431]]
• Joint Global Coordinators, Bookrunners, Lead Managers, Capital Market Intermediaries, Underwriters: Full list provided in the prospectus [[8], [33], [35]]
• Stabilization/Greenshoe: Syndicate members may engage in price stabilization activities, subject to legal restrictions [[288]]

With a reputable sponsor and comprehensive underwriting, the structure appears supportive of listing-day stability.

Company Overview: Business Model, Products, and Market Position

Hangzhou Diagens Biotechnology Co., Ltd. is a medical device company founded in 2016, specializing in AI-powered diagnostic solutions. The core product, AI AutoVision®, is the world’s first artificial intelligence karyotype diagnostic system, with MetaSight® as a complementary offering [[10], [136]].

• Revenue Streams: Sales of medical diagnostic devices and services.
• Key Products: AI AutoVision®, MetaSight® [[136]]
• Customer Segments: Hospitals, clinics, laboratories, medical institutions [[10]]
• Geographies: Primarily China, with plans for broader market penetration [[136]]
• Industry Definition: Medical device/biotechnology sector [[84]]

Market Position: The company possesses unique AI-driven diagnostics, with registration certificates obtained for flagship products, supporting its competitive edge.

Financial Health: Multi-Period Metrics and Ratios

Financial performance demonstrates solid margins and liquidity, with a focus on growth and R&D investment.

As of September 30, 2025, the company’s cash balance covers approximately 7.6 months of financial viability, or up to 132.8 months with IPO proceeds [[25]].

No material adverse change in financial position since September 30, 2025. Listing expenses total HK\$69.8 million, or about 8.4% of gross proceeds at the mid-point offer price [[26]].

Competitive Advantages, Brand Strength, and Management Team

Diagens is a pioneer in AI diagnostic technology, holding registration certificates and patents for its products. The brand is recognized for innovation in medical diagnostics, and the Pre-IPO investments signal confidence from sophisticated investors [[136]].

• Management Team: Led by Dr. Song, with a strong supporting cast of directors and senior managers specializing in biotechnology, medical devices, and AI [[9], [214]].
• Shareholding Structure: Pre-IPO controlling shareholders retain significant ownership post-IPO, with lock-up periods of 12 months [[143], [136]].

Industry Trends, Timing, and Market Environment

The IPO is timed amid robust demand for AI-driven medical solutions and regulatory support for biotechnology listings in Hong Kong.

• Sector Trend: Increasing adoption of AI in diagnostics, strong growth prospects for biotech companies [[84]].
• Timing: IPO window aligns with sectoral tailwinds; listing date is March 30, 2026 [[6]].
• Macro Indicators: Favorable market conditions described, driven by healthcare innovation and regulatory openness [[8]].
• Recent Developments: Multiple rounds of Pre-IPO investments totaling RMB397 million; valuation upon last round RMB2.6 billion [[27], [132]].

Market conditions appear supportive for a successful IPO.

Risk Factors: Regulatory, Operational, and Financial Exposures

Investors should note significant risks, including product development uncertainty, regulatory hurdles, and market volatility.

• Single Product Risk: AI AutoVision® is core; delays or failures in clinical development or commercialization could materially impact results [[25]].
• Regulatory Risk: Listing under Chapter 18A, with unique compliance requirements and waivers [[77], [78]].
• Market Risk: No prior public market; trading volume and price may be volatile [[69]].
• Competitive Risk: Rapid technological changes; competitors may develop superior products [[26]].
• Related Party Transactions: All conducted on an arm’s length basis; no distortion of historical results [[272]].
• Ownership Concentration: Significant post-IPO holdings by controlling shareholders [[143]].
• Other Risks: Data reliability, clinical trial challenges, acquisition/investment risks, and macroeconomic conditions [[25], [43]].

Growth Strategy: Expansion, Product Development, and Strategic Investments

Diagens plans aggressive R&D investment, market expansion, and strategic acquisitions.

• New Products: AI AutoVision® and MetaSight® registration and clinical expansion [[136]].
• Market Entry: Enhanced commercial capabilities and geographic expansion [[278]].
• M&A/Strategic Investment: Potential acquisitions and investments; no specific targets identified as of the prospectus [[278]].
• Capex Pipeline: Proceeds will fund technology upgrades and market development [[278]].

Ownership Structure and Lock-Up Periods

Post-IPO shareholding retains strong concentration among promoters and institutional investors, with lock-up periods ensuring alignment.

Valuation and Peer Comparison

IPO valuation is set at HK\$8,496.9 million to HK\$9,998.9 million, with adjusted net tangible assets per share of HK\$10.57–HK\$12.03 post-offering. No direct peer metrics or sector performance tables are disclosed in the prospectus [[373]].

No peer IPOs in the same period or sector performance tables disclosed.

Research, Analyst Coverage, and Opinions

No specific analyst coverage, price targets, or opinions are disclosed in the prospectus. Industry consultant Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. contributed sector and market insights [[31]].

IPO Allotment Results and Implications for Listing Day

Final subscription outcomes and allocation results will be published at www.iporesults.com.hk and www.eipo.com.hk/eIPOAllotment on March 27, 2026, with a 24-hour “search by ID” function [[302]]. Implications for listing-day performance will depend on oversubscription levels and investor demand.

Listing Outlook: Is Diagens Worth Subscribing?

Based strictly on prospectus disclosures, Hangzhou Diagens Biotechnology Co., Ltd. presents a high-growth, innovation-led opportunity with robust financial health and sector tailwinds. The combination of strong margins, liquidity, and market positioning, alongside reputable deal parties, suggests a favorable first-day trading range. If book-building results and oversubscription metrics are strong, the IPO could open above the mid-point of the offer price range and sustain upward momentum.

Risks remain significant, especially regarding product development and market volatility, but the company’s differentiated AI-driven offering and expansion plans position it well for growth.

Prospectus Access

Prospectus available at: www.hkexnews.hk and www.diagens.com

How to Apply for Diagens IPO Shares

Eligible investors (18+, Hong Kong address for White Form eIPO) may apply via:

• White Form eIPO service at www.eipo.com.hk
• HKSCC EIPO channel via brokers/custodians (HKSCC Participants)

Application window: March 20, 2026 (9:00 a.m.) to March 25, 2026 (12:00 noon). Results will be published on March 27, 2026 [[5], [296], [302]].